Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial.
Zamarin D, Walderich S, Holland A, Zhou Q, Iasonos AE, Torrisi JM, Merghoub T, Chesebrough LF, Mcdonnell AS, Gallagher JM, Li Y, Hollmann TJ, Grisham RN, Erskine CL, Block MS, Knutson KL, O'Cearbhaill RE, Aghajanian C, Konner JA.
Zamarin D, et al.
J Immunother Cancer. 2020 Jun;8(1):e000829. doi: 10.1136/jitc-2020-000829.
J Immunother Cancer. 2020.
PMID: 32503949
Free PMC article.
Clinical Trial.